TON - MARCH 2012 VOL 5, NO 2
In patients with chronic kidney disease (CKD), decreasing glomerular filtration rate (GFR) is associated with increased risk of kidney and urothelial cancer in a step-wise fashion, according to a large community-based study. An adjusted multivariate analysis found a 2-fold increase in risk of renal cancer and a substantially increased risk of urothelial cancer at GFR <30 mL/min/1.73 m2. The study was presented at the 2012 ASCO Genitourinary Cancers Symposium, held February 2-4 in San Francisco, California.
The University of Southern California (USC) Norris Comprehensive Cancer Center is part of the Keck School of Medicine and is designated by the National Cancer Institute as one of the nation’s 40 comprehensive cancer centers. Located in Los Angeles, the USC Norris Comprehensive Cancer Center serves as a regional and national resource for cancer treatment, research, prevention, and education.
Fear of genetic discrimination is often a stated barrier to referral to genetic counseling services and to willingness to undergo genetic testing.1,2 As a result, when the Genetic Information Nondiscrimination Act (GINA) was signed almost 4 years ago by President George W. Bush, many felt that this would be the panacea for individuals concerned about discrimination. GINA was the first federal legislation providing protections against genetic discrimination by health insurers and employers.
With this issue of The Oncology Nurse-APN/PA (TON), we cover everything from issues related to genetic discrimination to how a patient feels about her interaction with a doctor. Cristi Radford and Anya Prince provide specific information about the 2008 Genetic Info Information Nondiscrimination Act so oncology nurses can help their patients navigate the concerns about their medical records and health insurance coverage.
Patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials have worse outcomes on targeted therapy compared with eligible patients. In fact, extrapolating results of clinical trials to ineligible patients leads to inferior response rates (RRs), progression-free survival (PFS), and overall survival (OS).
Pain is a frequent and pervasive problem for older persons with cancer, affecting approximately 80% of this population.1 Treating older adults with cancer can be complex because of the presence of comorbid conditions that may impact chronic pain.2 Once pain is identified and the cause is known, it is sometimes necessary to target specific pain mechanisms.3 Hence, a comprehensive assessment of each individual patient is essential in order to identify all of the conditions contributing to pain.
Results 1 - 10 of 16